ArticleClinical, cosmetic and investigational dermatology2026
Baseline Clinical and Metabolic Predictors of 52-Week Durability of Secukinumab Response in Moderate-to-Severe Plaque Psoriasis.
Jiayue Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.